VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ CHB patients who had received single NAs for more  │ CHB patients who had received single NAs for more  │     100 │
│ than 12 months                                     │ than 12 months                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatitis B e antigen (HBeAg)-negative             │ Hepatitis B e antigen (HBeAg)-negative             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with other factors causing liver diseases │ Patients with other factors causing liver diseases │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant and lactating women                       │ Pregnant and lactating women                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with concomitant HIV infection or         │ Patients with concomitant HIV infection or         │     100 │
│ congenital immune deficiency diseases              │ congenital immune deficiency diseases              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with diabetes, autoimmune diseases        │ Patients with diabetes, autoimmune diseases        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with important organ dysfunctions         │ Patients with important organ dysfunctions         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with serious complications (e.g.,         │ Patients with serious complications (e.g.,         │     100 │
│ infection, hepatic encephalopathy, hepatorenal     │ infection, hepatic encephalopathy, hepatorenal     │         │
│ syndrome, gastrointestinal bleeding.)              │ syndrome, gastrointestinal bleeding.)              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who receive antineoplastic or             │ Patients who receive antineoplastic or             │     100 │
│ immunomodulatory therapy in the past 12 months     │ immunomodulatory therapy in the past 12 months     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a previous use of IFN anti hepatitis │ Patients with a previous use of IFN anti hepatitis │     100 │
│ B virus treatment or have NAs drug resistance      │ B virus treatment or have NAs drug resistance      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who can't come back to clinic for follow- │ Patients who can't come back to clinic for follow- │     100 │
│ up on schedule                                     │ up on schedule                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatitis B virus DNA \<100 IU/mL                  │ Hepatitis B virus DNA <100 IU/mL                   │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatitis B surface antigen (HBsAg) positive and   │ Hepatitis B surface antigen (HBsAg) positive and   │      99 │
│ \<1000 IU/mL                                       │ <1000 IU/mL                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with liver cirrhosis, Hepatocellular      │ Patients with liver cirrhosis, Hepatocellular      │      99 │
│ Carcinoma or AFP \>2 ULN or other malignancies     │ Carcinoma or AFP >2 ULN or other malignancies      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                               │   Score │
╞═══════════════════════════════════╪═════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Patients with diabetes, autoimmune diseases │      37 │
├───────────────────────────────────┼─────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 65 Years │ Patients with diabetes, autoimmune diseases │      39 │
╘═══════════════════════════════════╧═════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 96
Average Levenshtein Ratio of individual lines: 92.0
OverAll Ratio: 94.0
